SLS SELLAS Life Sciences Group Inc.

2.25
+0.06  (+3%)
Previous Close 2.19
Open 2.05
Price To Book 1.07
Market Cap 11,414,936
Shares 5,073,305
Volume 306,347
Short Ratio
Av. Daily Volume 429,496
Stock charts supplied by TradingView

NewsSee all news

  1. SELLAS Life Sciences Provides Regulatory Update for Nelipepimut-S (NPS) for Triple Negative Breast Cancer (TNBC) Following FDA Feedback

    NEW YORK, Feb. 14, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer

  2. SELLAS Announces Enrollment of First Patient in Phase 1 Trial of Galinpepimut-S (GPS) in Combination with Nivolumab (Opdivo®) in Patients with Malignant Pleural Mesothelioma (MPM)

    NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer

  3. SELLAS Names Dragan Cicic, MD, as Senior Vice President, Clinical Development

    NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer

  4. SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones

    - Phase 3 Galinpepimut-S (GPS) Acute Myeloid Leukemia (AML) Study Open for Enrollment and Patient Screening Underway -              - Regulatory Feedback Regarding Nelipepimut-S (NPS) in Triple Negative Breast Cancer

  5. SELLAS Announces Pricing of $6.5 Million Registered Direct Offering Priced At-The-Market

    NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial planned.
NeuVax in combination with Herceptin
Breast cancer - 1+/2+
Phase 1/2 interim data due 2H 2020.
Galinpepimut-S and Keytruda (pembrolizumab)
Solid tumors
Phase 3 trial initiation announced January 8, 2020 with interim data due 4Q 2021.
Galinpepimut-S
Acute Myeloid Leukemia (AML)
Phase 1 commencement of enrolment announced February 11, 2020.
Galinpepimut-S and nivolumab
Malignant pleural mesothelioma (MPM)
Phase 2 initial data due 1Q 2020.
Nelipepimut-S (NPS)
Ductal Carcinoma in Situ (DCIS)

Latest News

  1. SELLAS Life Sciences Provides Regulatory Update for Nelipepimut-S (NPS) for Triple Negative Breast Cancer (TNBC) Following FDA Feedback

    NEW YORK, Feb. 14, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer

  2. SELLAS Announces Enrollment of First Patient in Phase 1 Trial of Galinpepimut-S (GPS) in Combination with Nivolumab (Opdivo®) in Patients with Malignant Pleural Mesothelioma (MPM)

    NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer

  3. SELLAS Names Dragan Cicic, MD, as Senior Vice President, Clinical Development

    NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer

  4. SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones

    - Phase 3 Galinpepimut-S (GPS) Acute Myeloid Leukemia (AML) Study Open for Enrollment and Patient Screening Underway -              - Regulatory Feedback Regarding Nelipepimut-S (NPS) in Triple Negative Breast Cancer

  5. SELLAS Announces Pricing of $6.5 Million Registered Direct Offering Priced At-The-Market

    NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer

  6. SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML)

    -- Study Open for Enrollment and Patient Screening Underway -- NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical

  7. SELLAS to Present at Biotech Showcase™

    NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer

  8. SELLAS to Present at the 12th Annual LD Micro Main Event

    NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer

  9. SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results

    - Phase 3 Registrational Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) on Track to Initiate by Year End - - Clinically Significant Follow-up Data from Phase 1 Trial Continues to Support the Development

  10. SELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer Immunotherapy

    NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer

  11. SELLAS Announces Reverse Stock Split

    NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer